• Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. (unibo.it)
  • Here we report the results from a phase 2, single-arm, single-center trial evaluating the safety and efficacy of lenalidomide plus rituximab in elderly patients with relapsed or refractory DLBCL. (unibo.it)
  • Oral lenalidomide (20 mg/d for 21 days of each 28-day cycle) was initiated for four cycles and rituximab (375 mg/m(2)) was administered on day 1 and day 21 of each 28-day cycle for four cycles. (unibo.it)
  • CONCLUSION: Oral lenalidomide in combination with rituximab is active in elderly patients with relapsed/refractory DLBCL with a high percentage of patients achieving a continuous CR after lenalidomide maintenance. (unibo.it)
  • Purpose: We sought to improve upon frontline bendamustine/ rituximab (BR) induction therapy followed by rituximab maintenance in untreated high-risk follicular lymphoma (FL). (elsevierpure.com)
  • Patients and Methods: Patients were randomized to BR induction followed by 2-year rituximab maintenance (BR-R), BR with bortezomib and rituximab maintenance (BVR-R), or BR followed by lenalidomide (1 year) with rituximab maintenance (BR-LR). (elsevierpure.com)
  • Conclusions: Altogether, neither bortezomib added to BR induction nor lenalidomide added to rituximab maintenance immediately post-BR induction is recommended in untreated FL. (elsevierpure.com)
  • Eighteen patients (22.9%) received lenalidomide in combination with either dexamethasone (n = 13) or rituximab (n = 5). (unipg.it)
  • Epcoritamab + rituximab/lenalidomide resulted in high response rates in both first-line and R/R FL with no severe CRS events. (clinicaloptions.com)
  • This is an open-label, randomized, multicentre study to evaluate safety and preliminary efficacy of the human anti-CD19 antibody Tafasitamab in addition to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristin, Prednison) or Tafasitamab and Lenalidomide in addition to R-CHOP in adult patients with newly diagnosed, previously untreated Diffuse Large B-cell Lymphoma (DLBCL). (clinicaltrials.gov)
  • Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma. (vchri.ca)
  • Several studies 10 7 5 4 and a recent meta-analysis 1 have described a decrease in rates of CNS relapse in the post-rituximab era (probably due to improved control of systemic lymphoma), in addition to a change in the pattern of CNS relapse, with predominance of parenchymal over leptomeningeal relapse, isolated over combined (systemic plus CNS) relapses, and delayed CNS relapses. (haematologica.org)
  • A randomized phase III trial of consolidation with autologous hematopoietic cell transplantation followed by maintenance rituximab vs. maintenance rituximab alone for patients with mantle cell lymphoma in minimal residual disease-negative first complete remission. (slu.edu)
  • Venetoclax, lenalidomide and rituximab in patients with relapsed/refractory mantle cell lymphoma. (clinicaltrialsregister.eu)
  • An 84-year-old woman with evolutive mantle cell lymphoma who was receiving maintenance rituximab and lenalidomide treatment was admitted to the hospital on May 17, 2021. (cdc.gov)
  • This phase I trial is to find out the best dose, possible benefits and/or side effects of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. (wustl.edu)
  • The FDA announced that the Oncologic Drugs Advisory Committee (ODAC) will meet March 9 to review the accelerated approval of polatuzumab vedotin (Polivy) plus rituximab (Rituxan) and chemotherapy for untreated diffuse large B-cell lymphoma. (medpagetoday.com)
  • People with relapsed or refractory diffuse large B-cell lymphoma who cannot have an autologous stem cell transplant usually have polatuzumab vedotin plus rituximab and bendamustine. (bvsalud.org)
  • Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab. (cdc.gov)
  • Concomitant systemic lymphoma as well as transformation from follicular lymphoma and/or Chronic lymphocytic leukemia (CLL) to an aggressive B-cell histology is allowed. (ucbraid.org)
  • Together, they put half of the patients with relapsed follicular lymphoma into complete remission in a phase II clinical trial. (sciencedaily.com)
  • Such mild effects are particularly important for follicular lymphoma patients, who are diagnosed with the disease at a median age of 60. (sciencedaily.com)
  • Research showed PD1 is highly expressed on T cells in the bloodstream and tumors of follicular lymphoma patients and also is associated with impaired T cell function. (sciencedaily.com)
  • Follicular lymphoma is a cancer of B cells. (sciencedaily.com)
  • Idelalisib Speed Bump: Shifting Gears in CLL Dr Bruce Cheson discusses how the halt of six idelalisib trials because of adverse events, including deaths, affects research and patient management in CLL and follicular lymphoma. (medscape.com)
  • Let's dive right in and review the clinical implications of using bispecific antibodies and antibody-drug conjugates in follicular lymphoma. (reachmd.com)
  • So clearly, in follicular lymphoma, the times they are a-changing. (reachmd.com)
  • And against a historical backdrop where standard of care treatment of follicular lymphoma, we had chemoimmunotherapy, we have immunomodulatory drugs such as lenalidomide, and after that, we had no single standard of care. (reachmd.com)
  • We also have, on the horizon, the possible emergence of bispecific antibodies, such as polatuzumab vedotin and loncastuximab tesirine, which have clearly changed our management of aggressive B-cell lymphomas such as diffuse large B-cell lymphoma, and with emerging data suggesting that they may indeed play a role in the treatment of patients with relapsed or refractory follicular lymphoma. (reachmd.com)
  • So clearly, we have a broadening therapeutic armamentarium as we approach patients with relapsed or refractory follicular lymphoma that gives us, as oncologists, more opportunity to individualize our treatment programs for individual patients. (reachmd.com)
  • The antibody-drug conjugates, while none of these currently are approved in relapsed/refractory follicular lymphoma, we've seen them to be very promising in diffuse large B-cell lymphoma, and in general have manageable toxicity profiles. (reachmd.com)
  • It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. (investing.com)
  • and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. (investing.com)
  • There have been significant advancements in the management of follicular lymphoma (FL), the most common indolent lymphoma. (bvsalud.org)
  • To evaluate the relationship between tumor mutational profile and response to Tafasitamab plus lenalidomide, via whole exome sequencing of diagnostic specimens. (ucbraid.org)
  • To evaluate change in immune cell phenotypes in CSF and blood in patients via flow-cytometry of natural killer (NK) cell, T-cells and CSF monocytes/macrophages in patients treated with combination Tafasitamab plus lenalidomide. (ucbraid.org)
  • To evaluate the relationship between CSF cytokine microenvironment such as Interleukin-10 (IL-10), Chemokine ligand 13 (CXCL13), etc. as well as CSF metabolites, including energy metabolites and neurotransmitters, and response to combination Tafasitamab plus lenalidomide Tafasitamab, PFS, OS, and neurocognitive endpoints. (ucbraid.org)
  • It was seen that the drug combinations of lenalidomide plus dexamethasone and continuous bortezomib plus lenalidomide plus dexamethasone probably result in an increase of the overall survival. (wikipedia.org)
  • A total of 81 patients with previously treated DLBCL received tafasitamab plus lenalidomide for a maximum of 12 cycles, followed by tafasitamab maintenance. (medpagetoday.com)
  • The clinical evidence is from a small study that did not directly compare tafasitamab plus lenalidomide with any other trea. (bvsalud.org)
  • A year later, the combination of daratumumab plus bortezomib-and indeed daratumumab plus lenalidomide-is now FDA approved. (medscape.com)
  • Lenalidomide (REVLIMID). (healthline.com)
  • A CD19-targeted cytolytic antibody, tafasitamab has approval for use in combination with lenalidomide (Revlimid) in adults who are not eligible for autologous stem-cell transplantation. (medpagetoday.com)
  • Tafasitamab-cxix injection is used in adults along with lenalidomide (Revlimid) to treat certain types of non-Hodgkin's lymphoma (types of cancer that begin in a type of white blood cells that normally fights infection) that have returned or that did not respond to other treatments in those who cannot receive a stem cell transplant. (medlineplus.gov)
  • Discover different REVLIMID ® (lenalidomide) videos to help you learn more about your treatment. (revlimid.com)
  • What is REVLIMID ® (lenalidomide)? (revlimid.com)
  • Before you begin taking REVLIMID, you must read and agree to all of the instructions in the Lenalidomide REMS program. (revlimid.com)
  • Before prescribing REVLIMID, your healthcare provider will explain the Lenalidomide REMS program to you and have you sign the Patient-Physician Agreement Form. (revlimid.com)
  • Participants must have histologically or cytologically confirmed relapsed primary or secondary B-cell CNS lymphoma, DLBCL type (recurrence documented by flow-cytometry is also acceptable). (ucbraid.org)
  • DLBCL is a type of non-Hodgkin lymphoma (NHL). (survivornet.com)
  • BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive non-Hodgkin lymphoma and despite recent chemotherapeutic advances up to half of all patients relapse. (unibo.it)
  • The FDA granted accelerated approval for tafasitamab (Monjuvi) , the first approved second-line therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). (medpagetoday.com)
  • Several factors hinder the identification of risk factors for central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL), including the retrospective nature of most studies, the relatively low frequency of CNS relapse in DLBCL, and the heterogeneity of CNS prophylaxis methods used in these studies. (haematologica.org)
  • If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union - The positive opinion from the CHMP is. (financialcontent.com)
  • Anthracycline-containing therapy is the cornerstone of frontline treatment for diffuse large B-cell lymphoma (DLBCL), and autologous stem cell transplantation, and more recently, chimeric antigen receptor T-cell therapy are the primary treatment options for relapsed refractory DLBCL. (bvsalud.org)
  • it was frequently categorized as diffuse small-cleaved cell lymphoma (by the International Working Formulation) or centrocytic lymphoma (by the Kiel classification). (medscape.com)
  • 3 - 5 This report by the Spanish Lymphoma Group (GELTAMO) aims to provide useful guidelines and recommendations for the prevention, diagnosis, and treatment of central nervous system diffuse large B-cell lymphoma patients with, or at risk of, leptomeningeal and/or brain parenchyma lymphoma relapse. (haematologica.org)
  • HGBL, not otherwise specified (NOS) is a heterogeneous, aggressive, mature B-cell lymphoma that does not meet criteria for BL, DHL, or diffuse large B-cell lymphoma NOS. (cancernetwork.com)
  • Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas. (cdc.gov)
  • A high mutation rate of immunoglobulin heavy chain variable region gene associates with a poor survival and chemotherapy response of mantle cell lymphoma patients. (cdc.gov)
  • ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients. (cdc.gov)
  • For more information, see Non-Hodgkin Lymphoma and Pediatric Non-Hodgkin Lymphoma . (medscape.com)
  • Treatment protocols for classical Hodgkin lymphoma (HL) are provided below, including treatment for early-stage, advanced-stage, and relapsed/refractory disease. (medscape.com)
  • Cutaneous T-cell lymphoma (CTCL) is a type of non-Hodgkin lymphoma that originates in the skin. (lls.org)
  • Non-Hodgkin lymphoma (NHL) is the seventh most common cancer in the United States, with approximately 77,000 new cases and 20,000 deaths in 2020. (cancernetwork.com)
  • The Future of Hodgkin Lymphoma -- Brentuximab and Beyond Dr Bruce Cheson and Dr Ann LaCasce highlight data from ASH 2014 on brentuximab vedotin and discuss promising agents for Hodgkin lymphoma, including checkpoint inhibitors nivolumab and pembrolizumab. (medscape.com)
  • ASH 2014: If You're Going to San Francisco… Dr Bruce Cheson previews important data being presented at the upcoming ASH 2014 meeting, including studies of CLL, Hodgkin lymphoma, and the role of interim PET scans in large cell lymphoma. (medscape.com)
  • It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. (news-medical.net)
  • A new immunotherapy for companion dogs with advanced-stage non-Hodgkin lymphoma (NHL) has been shown to improve survival while maintaining quality of life, according to a study published in the journal Scientific Reports. (news-medical.net)
  • Our two most advanced therapeutic product programs target the HMTs DOT1L (for the treatment of mixed lineage leukemia, or MLL-r) and EZH2 (for a genetically defined subtype of non-Hodgkin lymphoma). (biospace.com)
  • AFM-13 is under development for the treatment of refractory and relapsed Hodgkin lymphoma, CD30+ lymphoma such as transformed mycosis fungoides, peripheral and cutaneous T-cell lymphoma, angioimmunoblastic T cell lymphoma, large B-cell lymphoma, B-cell non-Hodgkin lymphoma, Hodgkin lymphoma combination with check point inhibitors and Hodgkin lymphoma combination with lenalidomide. (pharmaceutical-technology.com)
  • The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population. (cdc.gov)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • Chanan-Khan noted that there are at least four ongoing trials with CAR T targeting either the B-cell maturation antigen (BCMA) alone or in combination with an anti-CD19 CAR T, immune checkpoint inhibitors, or with bortezomib, lenalidomide, and dexamethasone. (medscape.com)
  • Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. (nih.gov)
  • These include immunomodulatory agents such as lenalidomide, epigenetic modifiers (tazemetostat), and phosphoinotiside-3 kinase inhibitors (copanlisib). (bvsalud.org)
  • Lenalidomide is approved by FDA as a specialty drug requiring a specialty pharmacy distribution for mantle cell lymphoma in people whose disease has relapsed or progressed after at least two prior therapies, one of which must have included the medicine bortezomib. (wikipedia.org)
  • In fact, rrMCL became the first lymphoma for which four novel agents have been approved: temsirolimus, lenalidomide, ibrutinib, and bortezomib. (unipg.it)
  • Daratumumab in early relapse combined with bortezomib or lenalidomide is a new standard of care. (medscape.com)
  • Although preliminary, encouraging studies indicate that it can be added to standard induction regimens prior to transplant, such as bortezomib-lenalidomide-dexamethasone or carfilzomib-lenalidomide-dexamethasone. (medscape.com)
  • NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas, Version 5.2021. (medscape.com)
  • Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas. (news-medical.net)
  • Session: Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia. (businesswire.com)
  • An early-phase trial of the CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) in chronic lymphocytic leukemia/small lymphocytic lymphoma met the primary endpoint of objective response, Bristol Myers Squibb announced. (medpagetoday.com)
  • AFM-13 is under clinical development by Affimed and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). (pharmaceutical-technology.com)
  • According to GlobalData, Phase II drugs for Peripheral T-Cell Lymphomas (PTCL) have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. (pharmaceutical-technology.com)
  • Although not specifically approved by the FDA for use in treating AL amyloidosis, lenalidomide is sometimes used in the treatment of that condition, often in combination with dexamethasone. (wikipedia.org)
  • Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. (vchri.ca)
  • A large Italian study demonstrated the feasibility of using carfilzomib in frontline therapy combined with either cyclophosphamide - dexamethasone (KCD) or lenalidomide -dexamethasone (KRD). (medscape.com)
  • This is the first study to examine a naked anti-CD19 monoclonal antibody in relapsed CNS lymphoma patients as well as the combination of anti-CD19 antibody plus an Immunomodulatory imide drugs (IMiDs) in CNS lymphomas . (ucbraid.org)
  • To evaluate the clinical benefit rate of Tafasitamab in combination with lenalidomide in relapsed CNS lymphoma (Phase 2). (ucbraid.org)
  • BACKGROUND: Mantle cell lymphoma (MCL) has the worst prognosis of B-cell subtypes owing to its aggressive clinical disease course and incurability with standard chemo-immunotherapy. (unipg.it)
  • Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity. (medscape.com)
  • I expect that discoveries arising from these laboratory and clinical investigations will have relevance not only to CTCL but to other T cell lymphomas and potentially other malignancies. (lls.org)
  • In Lymphoma, Chemo Challenged by New Classes, New Combinations Drs Cheson and Flinn discuss lymphoma clinical trial data presented at the ASH 2015 meeting. (medscape.com)
  • R-squared Update: Underwhelms in FL, but Impressive in MCL Dr Bruce Cheson and Dr Nathan Fowler discuss lenalidomide clinical trial results at the 2014 ASH meeting, focusing on a trial presented by the Nordic Lymphoma Group. (medscape.com)
  • Her clinical and research interests lie in improving the outcomes of patients with lymphoma. (mdanderson.org)
  • Dr. Pinnix's ultimate aspiration is to advance the clinical outcomes of patients afflicted with Hodgkin's and Non-Hodgkin's lymphoma via the minimization of normal tissue toxicity related to radiotherapy. (mdanderson.org)
  • Clinical lymphoma, myeloma & leukemia 2018 8 18 (11): 762-768. (cdc.gov)
  • Clinical and functional impact of recurrent S1PR1 mutations in mantle cell lymphoma. (cdc.gov)
  • 2. Clinical epidemiology - using data from the Swedish Lymphoma Registry to provide clinically useful real world data on treatment and prognosis, in many cases in collaboration with Nordic colleagues. (lu.se)
  • Cutaneous T-cell lymphoma (CTCL) is a disfiguring, incurable malignancy profoundly affecting patients' appearances, quality of life, and relationships. (lls.org)
  • Adverse events more common in people receiving lenalidomide for myeloma include neutropenia, deep vein thrombosis, infections, and an increased risk of other hematological malignancies. (wikipedia.org)
  • Mantle cell lymphoma belongs to a group of diseases known as non-Hodgkin's lymphomas, which are related malignancies (cancers) that affect the lymphatic system. (rarediseases.org)
  • Aggressive B-cell malignancies, such as mantle cell lymphoma (MCL), are microenvironment-dependent tumors and a better understanding of the dialogs occurring in lymphoma-protective ecosystems will provide new perspectives to increase treatment efficiency. (haematologica.org)
  • Females who may become pregnant must use at least two forms of reliable contraception during treatment and for at least four weeks after discontinuing treatment with lenalidomide. (wikipedia.org)
  • IMPLICATION FOR PRACTICE: Several factors influence treatment choice in relapsed/refractory mantle cell lymphoma (rrMCL), and the therapeutic scenario is continuously evolving. (unipg.it)
  • Also commenting on the new results, ASCO Expert Oreofe Odejide, MD, of the Dana-Farber Cancer Institute in Boston, said in a statement: "Lenalidomide has become a foundation of care for people with myeloma, but as its use has expanded, so has the number of patients whose disease will no longer respond to the treatment. (medscape.com)
  • Lower-risk MDS patients with this deletion have responded well to treatment with lenalidomide. (healthline.com)
  • Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment. (medscape.com)
  • Mucosa-associated lymphoid tissue lymphoma of the stomach: long term outcome after local treatment. (medscape.com)
  • Dr. Song's research interests include the treatment of myeloma and other plasma cell dyscrasias and the use of hematopoietic stem cell transplant to treat non-Hodgkin's lymphoma. (vchri.ca)
  • Gene expression analysis of tumor samples from 18 patients before treatment showed that progression-free survival increased for patients when their gene signature included genes that are highly active during T cell response or repressed in regulatory T cells that dampen T cell activation," said Eric Davis, M.D., associate professor of Lymphoma/Myeloma and co-senior author of the paper. (sciencedaily.com)
  • European Commission (EC) approves Minjuvi with lenalidomide for the treatment of large B-cell lymphoma in adults. (europeanpharmaceuticalreview.com)
  • This study may help increase the understanding of lenalidomide and nivolumab use in primary CNS lymphoma treatment. (wustl.edu)
  • Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy. (news-medical.net)
  • Another interest lies in the identification of improved treatment strategies that incorporate radiation in the management of aggressive and refractory lymphomas. (mdanderson.org)
  • We are currently investigating how immune checkpoint proteins together with the immune booster lenalidomide affect CTCL growth. (lls.org)
  • After this induction phase, patients achieving a complete response (CR), partial response (PR), or stable disease (SD) were given lenalidomide maintenance therapy at the same schedule for another 8 months. (unibo.it)
  • CONCLUSION: Lenalidomide therapy for relapsed MCL patients is effective and tolerable even in a real-life context. (unipg.it)
  • In addition, it may help researchers see whether the control of CNS lymphoma can be extended by using these study drugs as maintenance (prolonged therapy) after control is achieved with the initial chemotherapy regimen (induction). (wustl.edu)
  • Rates of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) Data on U.S. Subjects (SUBJ) with Lymphoma Following Chimeric Antigen Receptor T Cell (CAR-T) Therapy (Abstract #7528. (businesswire.com)
  • KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. (cdc.gov)
  • CAR (chimeric antigen receptor) T-cell therapy is the latest wave in hematology and has been validated in various forms of leukemia and lymphoma . (medscape.com)
  • This is a single arm open-label multicenter phase I/II investigation of combination lenalidomide/Tafasitamab in patients with relapsed central nervous system (CNS) lymphoma. (ucbraid.org)
  • To determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of lenalidomide in combination with Tafasitamab in patients with relapsed central nervous system (CNS) lymphoma (Phase 1). (ucbraid.org)
  • This is a single arm open-label multicenter phase I/II investigation of combination lenalidomide/Tafasitamab in patients with relapsed CNS lymphoma.During the phase 1 portion of the study, the investigators will examine three dose levels of Lenalidomide (10mg, 15mg and 20mg) in combination with Tafasitamab at a dose of 12 mg/kg. (ucbraid.org)
  • Phase 1b will assess dose-limiting toxicities of maplirpacept (PF-07901801) when administered in combination with tafasitamab and lenalidomide, to select up to 2 doses for the Phase 2 part of the study. (survivornet.com)
  • Phase 2 will evaluate safety and efficacy to determine the recommended Phase 3 dose of Maplirpacept (PF-07901801) to be administered in combination with tafasitamab and lenalidomide. (survivornet.com)
  • The aggressive B-cell lymphomas BL, DHL, and HGBL, NOS are unique diseases with specific pathogenesis and biology. (cancernetwork.com)
  • These data uncovered the IL32β/BAFF axis as a previously undescribed pathway involved in lymphoma-associated macrophage polarization and tumor survival, which could be counteracted through selective NIK inhibition. (haematologica.org)
  • Lenalidomide may stop or slow primary CNS lymphoma by blocking the growth of new blood vessels necessary for tumor growth. (wustl.edu)
  • 1 A significant minority of these cases were the especially aggressive B-cell lymphomas Burkitt lymphoma (BL) and high-grade B-cell lymphoma (HGBL), the latter of which includes the histologic subtypes HGBL with MYC and BCL2 and/or BCL6 translocations (conventionally referred to as double-hit lymphoma [DHL]) and HGBL, not otherwise specified (NOS). (cancernetwork.com)
  • TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. (cdc.gov)
  • A panel of lymphoma experts working on behalf of GELTAMO reviewed all data published on these topics available in PubMed up to May 2016. (haematologica.org)
  • Lenalidomide is effective at inducing a complete or "very good partial" response and improves progression-free survival. (wikipedia.org)
  • The area of research for our group is malignant lymphomas - all possible aspects, aiming for the improvement of the quality of life and survival of these patients. (lu.se)
  • To describe the toxicities of Tafasitamab in combination with lenalidomide in relapsed CNS lymphoma. (ucbraid.org)
  • To obtain pilot information about CSF penetration of Tafasitamab as well as CSF partition coefficient of lenalidomide in combination with Tafasitamab to evaluate possibility that Tafasitamab enhances CSF penetration of lenalidomide to an extent greater than CSF/plasma partition coefficient of lenalidomide which was 20% at 15 and 20 milligram (mg) dose levels. (ucbraid.org)
  • To test the hypothesis that Tafasitamab in combination with lenalidomide impacts blood-brain barrier permeability associated with CNS lymphoma lesions, as assessed by albumin levels and MRI vascular permeability imaging metrics. (ucbraid.org)
  • Patients who received lenalidomide alone were compared with patients who received lenalidomide in combination: OS and DFS did not differ. (unipg.it)
  • Progression-free survivals are significantly different: at 56 months, 36% in the combination group versus 13% in patients who received lenalidomide alone. (unipg.it)
  • ASH 2015: For Lymphoma, CLL, the Action Is in Combinations Dr Bruce Cheson previews data to be presented at the upcoming ASH 2015 meeting, the most exciting of which are from studies using combination drugs. (medscape.com)
  • The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. (lls.org)